{
  "paper_id": "85b87a183b82a57846e65afdeeaa52b2d8f206f6",
  "metadata": {
    "title": "Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild- Type Glycoproteins in a Phase I Clinical Trial",
    "coda_data_split": "dev",
    "coda_paper_id": 1653,
    "coda_has_expert_labels": false,
    "subset": "custom_license"
  },
  "abstract": [
    {
      "original_text": "Background. Ebolavirus and Marburgvirus cause severe hemorrhagic fever with high mortality and are potential bioterrorism agents. There are no available vaccines or therapeutic agents. Previous clinical trials evaluated transmembrane-deleted and point-mutation Ebolavirus glycoproteins (GPs) in candidate vaccines. Constructs evaluated in this trial encode wild-type (WT) GP from Ebolavirus Zaire and Sudan species and the Marburgvirus Angola strain expressed in a DNA vaccine.",
      "sentences": [
        [
          {
            "segment_text": "Background .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Ebolavirus and Marburgvirus cause severe hemorrhagic fever with high mortality and are potential bioterrorism agents .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "There are no available vaccines or therapeutic agents .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Previous clinical trials evaluated transmembrane-deleted and point-mutation Ebolavirus glycoproteins ( GPs ) in candidate vaccines .",
            "crowd_label": "background"
          }
        ],
        [
          {
            "segment_text": "Constructs evaluated in this trial encode wild-type ( WT ) GP from Ebolavirus Zaire and Sudan species and the Marburgvirus Angola strain expressed in a DNA vaccine .",
            "crowd_label": "background"
          }
        ]
      ]
    },
    {
      "original_text": "Methods. The VRC 206 study evaluated the safety and immunogenicity of these DNA vaccines (4 mg administered intramuscularly by Biojector) at weeks 0, 4, and 8, with a homologous boost at or after week 32. Safety evaluations included solicited reactogenicity and coagulation parameters. Primary immune assessment was done by means of GP-specific enzyme-linked immunosorbent assay.",
      "sentences": [
        [
          {
            "segment_text": "Methods .",
            "crowd_label": "method"
          }
        ],
        [
          {
            "segment_text": "The VRC 206 study evaluated the safety and immunogenicity of these DNA vaccines ( 4 mg administered intramuscularly by Biojector ) at weeks 0 ,",
            "crowd_label": "method"
          },
          {
            "segment_text": "4 , and 8 , with a homologous boost at or after week 32 .",
            "crowd_label": "method"
          }
        ],
        [
          {
            "segment_text": "Safety evaluations included solicited reactogenicity and coagulation parameters .",
            "crowd_label": "method"
          }
        ],
        [
          {
            "segment_text": "Primary immune assessment was done by means of GP-specific enzyme-linked immunosorbent assay .",
            "crowd_label": "method"
          }
        ]
      ]
    },
    {
      "original_text": "Results. The vaccines were well tolerated, with no serious adverse events; 80% of subjects had positive enzymelinked immunosorbent assay results (≥30) at week 12. The fourth DNA vaccination boosted the immune responses.",
      "sentences": [
        [
          {
            "segment_text": "Results .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "The vaccines were well tolerated ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "with no serious adverse events ; 80 % of subjects had positive enzymelinked immunosorbent assay results ( ≥ 30 ) at week 12 .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "The fourth DNA vaccination boosted the immune responses .",
            "crowd_label": "finding"
          }
        ]
      ]
    },
    {
      "original_text": "Conclusions. The investigational Ebolavirus and Marburgvirus WT GP DNA vaccines were safe, well tolerated, and immunogenic in this phase I study. These results will further inform filovirus vaccine research toward a goal of inducing protective immunity by using WT GP antigens in candidate vaccine regimens.",
      "sentences": [
        [
          {
            "segment_text": "Conclusions .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "The investigational Ebolavirus and Marburgvirus WT GP DNA vaccines were safe ,",
            "crowd_label": "finding"
          },
          {
            "segment_text": "well tolerated , and immunogenic in this phase I study .",
            "crowd_label": "finding"
          }
        ],
        [
          {
            "segment_text": "These results will further inform filovirus vaccine research toward a goal of inducing protective immunity by using WT GP antigens in candidate vaccine regimens .",
            "crowd_label": "finding"
          }
        ]
      ]
    },
    {
      "original_text": "Clinical Trials Registration. NCT00605514.",
      "sentences": [
        [
          {
            "segment_text": "Clinical Trials Registration .",
            "crowd_label": "other"
          }
        ],
        [
          {
            "segment_text": "NCT00605514 .",
            "crowd_label": "other"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "5",
    "sentence_num": "17",
    "segment_num": "20",
    "token_num": "232"
  }
}